Studies of locomotor network neuroprotection by the selective poly(ADP-ribose) polymerase-1 inhibitor PJ-34 against excitotoxic injury to the rat spinal cord in vitro

被引:16
|
作者
Nasrabady, Sara E. [1 ]
Kuzhandaivel, Anujaianthi [1 ]
Nistri, Andrea [1 ,2 ]
机构
[1] Int Sch Adv Studies SISSA, Neurobiol Sect, I-34136 Trieste, Italy
[2] Ist Fis Med & Riabilitaz, Spinal Person Injury Neurorehabil Appl Lab, Udine, Italy
关键词
central pattern generator; fictive locomotion; kainate; kainic acid; motoneuron; parthanatos; APOPTOSIS-INDUCING FACTOR; CENTRAL PATTERN GENERATORS; FOCAL CEREBRAL-ISCHEMIA; NEURONAL CELL-DEATH; NEONATAL-RAT; NUCLEAR TRANSLOCATION; GENE DISRUPTION; SLICE CULTURES; BRAIN-INJURY; CIRCUITS;
D O I
10.1111/j.1460-9568.2011.07714.x
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Delayed neuronal destruction after acute spinal injury is attributed to excitotoxicity mediated by hyperactivation of poly(ADP-ribose) polymerase-1 (PARP-1) that induces 'parthanatos', namely a non-apoptotic cell death mechanism. With an in vitro model of excitotoxicity, we have previously observed parthanatos of rat spinal cord locomotor networks to be decreased by a broad spectrum PARP-1 inhibitor. The present study investigated whether the selective PARP-1 inhibitor N-(6-oxo-5,6-dihydrophenanthridin-2-yl)(N,N-dimethylamino)acetamide center dot HCl (PJ-34) not only protected networks from kainate-evoked excitotoxicity, but also prevented loss of locomotor patterns recorded as fictive locomotion from lumbar (L) ventral roots (VRs) 24 h later. PJ-34 (60 mu m) blocked PARP-1 activation and preserved dorsal, central and ventral gray matter with maintained reflex activity even after a large dose of kainate. Fictive locomotion could not, however, be restored by either electrical stimulation or bath-applied neurochemicals (N-methyl-D-aspartate plus 5-hydroxytryptamine). A low kainate concentration induced less histological damage that was widely prevented by PJ34. Nonetheless, fictive locomotion was observed in just over 50% of preparations whose histological profile did not differ (except for the dorsal horn) from those lacking such a rhythm. Our data show that inhibition of PARP-1 could amply preserve spinal network histology after excitotoxicity, with return of locomotor patterns only when the excitotoxic stimulus was moderate. These results demonstrated divergence between histological and functional outcome, implying a narrow borderline between loss of fictive locomotion and neuronal preservation. Our data suggest that either damage of a few unidentified neurons or functional network inhibition was critical for ensuring locomotor cycles.
引用
收藏
页码:2216 / 2227
页数:12
相关论文
共 50 条
  • [21] Local administration of the poly ADP-ribose polymerase (PARP) inhibitor, PJ34 during hindlimb ischemia modulates skeletal muscle reperfusion injury
    Conrad, Mark F.
    Albadawi, Hassan
    Stone, David H.
    Crawford, Robert S.
    Entabi, Fateh
    Watkins, Michael T.
    JOURNAL OF SURGICAL RESEARCH, 2006, 135 (02) : 233 - 237
  • [22] PROTECTIVE ACTIONS OF PJ34, A POLY(ADP-RIBOSE)POLYMERASE INHIBITOR, ON THE BLOOD-BRAIN BARRIER AFTER TRAUMATIC BRAIN INJURY IN MICE
    Tao, X.
    Chen, X.
    Hao, S.
    Hou, Z.
    Lu, T.
    Sun, M.
    Liu, B.
    NEUROSCIENCE, 2015, 291 : 26 - 36
  • [23] A novel poly(ADP-ribose) polymerase inhibitor, PJ34, improves cardiac function and vascular relaxation in rat model of chronic heart failure
    Pacher, P
    Liaudet, L
    Mabley, JG
    Szabo, C
    FASEB JOURNAL, 2002, 16 (04): : A176 - A176
  • [24] Role of ABT888, a Novel Poly(ADP-Ribose) Polymerase (PARP) Inhibitor in Countering Autophagy and Apoptotic Processes Associated to Spinal Cord Injury
    Casili, Giovanna
    Campolo, Michela
    Lanza, Marika
    Filippone, Alessia
    Scuderi, Sarah
    Messina, Salvatore
    Ardizzone, Alessio
    Esposito, Emanuela
    Paterniti, Irene
    MOLECULAR NEUROBIOLOGY, 2020, 57 (11) : 4394 - 4407
  • [25] Role of ABT888, a Novel Poly(ADP-Ribose) Polymerase (PARP) Inhibitor in Countering Autophagy and Apoptotic Processes Associated to Spinal Cord Injury
    Giovanna Casili
    Michela Campolo
    Marika Lanza
    Alessia Filippone
    Sarah Scuderi
    Salvatore Messina
    Alessio Ardizzone
    Emanuela Esposito
    Irene Paterniti
    Molecular Neurobiology, 2020, 57 : 4394 - 4407
  • [26] Increased in vitro and in vivo sensitivity of BRCA2-associated pancreatic cancer to the poly(ADP-ribose) polymerase-1/2 inhibitor BMN 673
    Andrei, Alexandra-Zoe
    Hall, Anita
    Smith, Alyssa L.
    Bascunana, Claire
    Malina, Abba
    Connor, Ashton
    Altinel-Omeroglu, Gulbeyaz
    Huang, Sidong
    Pelletier, Jerry
    Huntsman, David
    Gallinger, Steven
    Omeroglu, Atilla
    Metrakos, Peter
    Zogopoulos, George
    CANCER LETTERS, 2015, 364 (01) : 8 - 16
  • [27] Poly(ADP-Ribose) Polymerase-1 Mediates Angiotensin II-Induced Expression of Plasminogen Activator Inhibitor-1 and Fibronectin in Rat Mesangial Cells
    Zhu, Hengmei
    Jiang, Zongpei
    Lei, Ping
    Huang, Wen
    Yu, Xueqing
    KIDNEY & BLOOD PRESSURE RESEARCH, 2011, 34 (05): : 320 - 327
  • [28] Treatment with the poly(ADP-ribose) polymerase inhibitor PJ-34 improves cerebromicrovascular endothelial function, neurovascular coupling responses and cognitive performance in aged mice, supporting the NAD+ depletion hypothesis of neurovascular aging
    Tarantini, Stefano
    Yabluchanskiy, Andriy
    Csipo, Tamas
    Fulop, Gabor
    Kiss, Tamas
    Balasubramanian, Priya
    DelFavero, Jordan
    Ahire, Chetan
    Ungvari, Anna
    Nyul-Toth, Adam
    Farkas, Eszter
    Benyo, Zoltan
    Toth, Attila
    Csiszar, Anna
    Ungvari, Zoltan
    FASEB JOURNAL, 2020, 34
  • [29] Neuroprotective effects of a novel water-soluble poly(ADP-ribose) polymerase-1 inhibitor, MP-124, in in vitro and in vivo models of cerebral ischemia
    Egi, Yasuhiro
    Matsuura, Shigeru
    Maruyama, Tomoyuki
    Fujio, Masakazu
    Yuki, Satoshi
    Akira, Toshiaki
    BRAIN RESEARCH, 2011, 1389 : 169 - 176
  • [30] Systemic administration of GPI 15427, a novel Poly(ADP-Ribose) polymerase-1 inhibitor, increases the antitumor activity of temozolomide against intracranial melanoma, glioma, lymphoma
    Tentori, L
    Leonetti, C
    Scarsella, M
    d'Amati, G
    Vergati, M
    Portarena, I
    Xu, WZ
    Kalish, V
    Zupi, G
    Zhang, J
    Graziani, G
    CLINICAL CANCER RESEARCH, 2003, 9 (14) : 5370 - 5379